SQLite Web: event_store.db

Update row sig_0974d89f24e7 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003240.txt","as_of":"2026-04-08T19:57:42.365437+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003240.txt","company":"Zeo ScientifiX, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003240.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_4beb8cc0a50ee7c9","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003240.txt","content_type":"text/plain","enriched_at":"2026-04-08T22:05:58.365663+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003240.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003240.txt","source_event_id":"evt_84b87082a82a","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"8-K","fp":"c98c42dfd242c742","kind":"sec_filing","published_at":"20260407","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-07","2026-04-08","Tuesday, April 7, 2026"],"entities":[{"asset_class":"equity","name":"Zeo ScientifiX, Inc.","relevance":"high","symbol":"ZEOX","type":"issuer"},{"asset_class":"other","name":"XPRIZE Healthspan","relevance":"high","symbol":"","type":"competition"},{"asset_class":"other","name":"Nova Southeastern University","relevance":"medium","symbol":"","type":"institution"},{"asset_class":"other","name":"American Academy of Anti-Aging Medicine (A4M)","relevance":"low","symbol":"","type":"organization"},{"asset_class":"other","name":"Ian T. Bothwell","relevance":"medium","symbol":"","type":"person"},{"asset_class":"other","name":"Dr. George C. Shapiro, MD, FACC","relevance":"low","symbol":"","type":"person"}],"event_type":"listing","information_gaps":["What changed versus prior known state is not explicitly provided in the signal; only that this 8-K reports the Semi-Finals selection is disclosed.","The specific details of the prior state (e.g., whether ZEO was previously only in Qualifying Submission stage) are not stated in the provided text.","The full contents of the press release are truncated at the end in the provided cleaned text (Forward-Looking Statements section appears cut off)."],"key_facts":["The company filed a Form 8-K with Item 8.01 Other Events.","The earliest event reported is April 7, 2026.","ZEO announced it was selected as a Qualified Team advancing into the Semi-Finals stage of the XPRIZE Healthspan competition.","A copy of the press release is included as Exhibit 99.1.","The press release states the competition is a $101 million global competition designed to revolutionize human aging by developing therapeutics to restore muscle, cognitive, and immune function by a minimum of 10 years (goal of 20 years) in persons aged 65-80 years, in one year or less.","The press release states ZEO is preparing its Finals Application following review of its Qualifying Submission by XPRIZE Healthspan judges.","The press release describes ZEO\u2019s therapeutic platform as regenerative biologics, specifically extracellular vesicle (exosome) therapeutics and next-generation delivery systems.","The press release states ZEO operates advanced laboratory facilities within the Center for Collaborative Research at Nova Southeastern University.","The press release states that during the Semi-Finals stage, ZEO will seek to advance its therapeutic platform into controlled clinical evaluation to generate human data on safety, biological activity, and functional outcomes across muscle, cognition, and immune function.","The press release states the data generated is expected to support execution of controlled clinical trials aligned with XPRIZE Healthspan\u2019s objectives.","The press release states this achievement follows ZEO\u2019s recent appointment as the official regenerative medicine educational partner for A4M."],"numeric_claims":[{"label":"Competition prize amount (USD)","value":"101 million"},{"label":"Minimum functional improvement target (years)","value":"10"},{"label":"Goal functional improvement target (years)","value":"20"},{"label":"Target age range","value":"65-80"},{"label":"Timeframe to achieve outcome (years)","value":"1"}],"primary_claim":"On April 7, 2026, ZEO issued a press release announcing its selection as a Qualified Team advancing into the Semi-Finals stage of the XPRIZE Healthspan competition.","relevance_score":0.62,"sentiment":"positive","source_quality":"high","summary":"Zeo ScientifiX, Inc. (OTCQB: ZEOX) filed a Form 8-K on April 7, 2026 to report that it was selected as a Qualified Team advancing to the Semi-Finals stage of the XPRIZE Healthspan competition. The filing includes Exhibit 99.1 containing the related press release.","topics":["SEC filing","Form 8-K","XPRIZE Healthspan","Semi-Finals selection","press release","regenerative biologics","exosome therapeutics","clinical evaluation","OTCQB: ZEOX"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 8-K \u00b7 Zeo ScientifiX, Inc. \u00b7 Filed 20260407","ticker":"ZEOX","tickers":["ZEOX"],"title":"ZEOX filed 8-K","url":"https://www.sec.gov/Archives/edgar/data/1557376/0001829126-26-003240.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel